With so much variation, why force local affiliates to use the global agency?This is a battle seldom worth the fight.
The epitome of global marketing is characterized by a highly centralized, consistent, and efficient brand platform that provides the organization with increased return on their marketing investment. Ideally, the brand platform would achieve global relevance, consistent from market to market. Although theoretically ideal, this is rarely achieved. Most often, we accept somewhere in the middle as being "just right"—a consistent global brand injected with local relevance.
Ken Begasse Jr
Before working with our clients globally, we do an analysis of the Global Universal Truths (GUTs) to determine what level of globalization is achievable. Our 6-point GUT Check identifies similarities and differences across markets.
Disease: Does the disease affect the populations in key markets similarly?
Guidelines: Do medical practitioners use similar treatment algorithms?
Treatments: Do medical practitioners have similar access to treatment options?
Policy: Does the healthcare system policy create market-to-market differences in the competitive set?
Culture: Are there cultural idiosyncrasies that shape customer attitudes toward the disease or treatment?
Organization: What are the resources of the organization within key markets?
In the end, the process helps to determine where global activities end and local activities begin.
The global team and agency simply need to provide a unified brand strategy, essence, and identity, with clear direction for local market adaptation. Then the organization can work collaboratively with local markets to address strategic issues or capitalize on local opportunities. This enhances the brand's local relevancy while globally amortizing key brand expenditures across markets.
Recently, we performed a number of branding and packaging assignments for a global client. China was the main market, along with other Asian and Middle Eastern countries. Most significantly in China, what we learned confirmed the willingness of families to purchase premium products above those already available. Even in a global economic crisis, there wasn't a cost ceiling for a fully supported premium brand. Product X contained a medical or scientific advantage. These advancements were branded to elevate their end benefit; however, it was evident that packaging played a more significant role in selection. In some instances, parents would be willing to work additional jobs to provide this product to their children. After purchase, the marketer must continually reinforce their customer's purchase decision with a mix of mass-marketing brand building that justifies their expense with more individual, value-added mobile and digital educational support that increases their satisfaction.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.